Your browser doesn't support javascript.
loading
Large Mesenteric Gaucheroma Responds to Substrate Reduction Therapy: A New Management of Gaucheromas.
Yano, Shoji; Moseley, Kathryn; Mahajan, Neha; Warren, Mikako; Vachon, Linda.
Afiliación
  • Yano S; Division of Genetics, Department of Pediatrics, Los Angeles County + USC Medical Center, University of Southern California, Los Angeles, California, United States.
  • Moseley K; Division of Genetics, Department of Pediatrics, Los Angeles County + USC Medical Center, University of Southern California, Los Angeles, California, United States.
  • Mahajan N; Department of Pediatrics, Los Angeles County + USC Medical Center, University of Southern California, Los Angeles, California, United States.
  • Warren M; Department of Pathology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, United States.
  • Vachon L; Department of Radiology, Los Angeles County + USC Medical Center, University of Southern California, Los Angeles, California, United States.
J Pediatr Genet ; 11(1): 47-50, 2022 Mar.
Article en En | MEDLINE | ID: mdl-35186390
ABSTRACT
Gaucheromas, which are pseudotumors consisting of a cluster of Gaucher cells, are rare complications in Gaucher's disease (GD) and reported in patients treated with enzyme replacement therapy (ERT). Gaucheromas commonly develop in the lymph nodes in the mesenteric and mediastinal regions and can cause serious complications including protein-losing enteropathy. A large mesenteric Gaucheroma showed a significant reduction in size after initiation of substrate reduction therapy (SRT) with eliglustat in an adult patient with GD type 3. Combination therapy with ERT and SRT should be considered to prevent Gaucheromas in patients with GD.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Pediatr Genet Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Pediatr Genet Año: 2022 Tipo del documento: Article